Gouty Arthritis (Gout) Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

This reports provides a data-driven overview of the current and future competitive landscape in Gout therapeutics.

Synopsis

• In 2022, there will be more than 30 million diagnosed prevalent cases of gout across 16 pharmaceutical markets
• The majority of marketed drugs for the treatment of gout fall into the enzyme inhibitor and receptor agonist mechanism of action category
• The gout pipeline consists of 65 pharmaceuticals spanning all stages of development, with approximately 53% of drugs in early-stage development
• Commercial sponsors dominate clinical trial development in gout, with the US and China emerging as the key countries for conducting trials in gout
• Deals involving acquisitions and licensing assets were the two most common type of deals globally
• The strategy for many of the key players in the gout space has been to to maintain their position in the mature and highly genericized gout market

Scope

GlobalData's Gouty Arthritis (Gout) Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Gout market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Gout market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.